悦康药业集团股份有限公司简式权益变动报告书 悦康药业集团股份有限公司 上市公司名称：悦康药业集团股份有限公司 股票简称：悦康药业 股票代码：688658 上市地点：上海证券交易所 信息披露义务人名称：阜阳京悦永顺信息咨询有限公司 住所：安徽省阜阳市颍东区新华街道富颍路 70 号院内五楼 503 室 通讯地址：安徽省阜阳市颍东区新华街道富颍路 70 号院内五楼 503 室 信息披露义务人一致行动人 1：菏泽三荣股权投资合伙企业（有限合伙） 主要经营场所：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区-11 通讯地址：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区 -11 信息披露义务人一致行动人 2：菏泽峰胜股权投资合伙企业（有限合伙） 主要经营场所：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区-9 通讯地址：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区 -9 信息披露义务人一致行动人 3：菏泽锦然股权投资合伙企业（有限合伙） 悦康药业集团股份有限公司简式权益变动报告书 主要经营场所：山东省菏泽市牡丹区牡丹街道 ...

公司已对京悦永顺持有本公司的 41,768,846 股股份被冻结的相关情况进行 了 披 露 ， 具 体 详 见 公 司 于 2025 年 4 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及指定媒体披露的《悦康药业集团股份有限公司关于控股股 东部分股份被冻结的公告》（公告编号：2025-020）。 二、本次控股股东持有公司股份被解除冻结的情况 近日，公司控股股东京悦永顺收到北京市第二中级人民法院执行裁定书 （（2025）京 02 执恢 18 号），并转达公司。京悦永顺所持公司股份因司法拍卖的 站（www.sse.com.cn）及指定媒体披露的《关于公司控股股东所持部分股份被司 法拍卖完成过户登记暨权益变动跨越 5%整数倍的提示性公告》（公告编号： 经解除冻结。具体情况如下： 证券代码：688658 证券简称：悦康药业 公告编号：2025-035 悦康药业集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 悦康药业集团股份有限公司（以下简称"公司"）控 ...

Group 1 - The core point of the news is that Yuekang Pharmaceutical has had a significant portion of its shares released from judicial freeze, which may positively impact its stock performance and investor confidence [1] - As of the announcement date, the controlling shareholder, Jingyue Yongshun, holds a total of 153,740,120 shares in the company, with 5,670,654 shares still frozen [1] - The revenue composition for Yuekang Pharmaceutical for the year 2024 is as follows: 96.19% from pharmaceutical manufacturing, 3.46% from pharmaceutical agency, and 0.36% from other businesses [1] Group 2 - The current market capitalization of Yuekang Pharmaceutical is 14.5 billion yuan [2]

悦康药业集团股份有限公司 简式权益变动报告书 上市公司名称：悦康药业集团股份有限公司 股票简称：悦康药业 悦康药业集团股份有限公司简式权益变动报告书 股票代码：688658 上市地点：上海证券交易所 信息披露义务人名称：阜阳京悦永顺信息咨询有限公司 住所：安徽省阜阳市颍东区新华街道富颍路 70 号院内五楼 503 室 通讯地址：安徽省阜阳市颍东区新华街道富颍路 70 号院内五楼 503 室 信息披露义务人一致行动人 1：菏泽三荣股权投资合伙企业（有限合伙） 主要经营场所：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区-11 通讯地址：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区 -11 信息披露义务人一致行动人 2：菏泽峰胜股权投资合伙企业（有限合伙） 主要经营场所：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区-9 通讯地址：山东省菏泽市牡丹区牡丹街道 240 国道新经济产业园 A3 座 A 区 -9 信息披露义务人一致行动人 3：菏泽锦然股权投资合伙企业（有限合伙） 1 悦康药业集团股份有限公司简式权益变动报告书 主要经营场所：山东 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-034 悦康药业集团股份有限公司 关于公司控股股东所持部分股份被司法拍卖完成过 户登记暨权益变动跨越 5%整数倍的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动系悦康药业集团股份有限公司（以下简称"公司"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有的公司 26,500,000 股无限售流通股股票被司法拍卖完成过户登记所致。 本次权益变动前，公司控股股东京悦永顺持有公司股份为 180,240,120 股， 占公司总股本的 40.05%。公司控股股东及其一致行动人共同持有公司 245,447,562 股，占公司总股本的 54.54%。本次权益变动后，公司控股股东 京悦永顺持有公司股份为 153,740,120 股，占公司总股本的 34.16%。公司控 股股东及其一致行动人共同持有公司股份数量变为 218,947,562 股，占公司 总股本的 48.66%。 本次权益变动属于执行法院裁定导致的被动减持 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-035 悦康药业集团股份有限公司 关于控股股东部分股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次解除冻结的股份原冻结情况 公司已对京悦永顺持有本公司的 41,768,846 股股份被冻结的相关情况进行 了 披 露 ， 具 体 详 见 公 司 于 2025 年 4 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及指定媒体披露的《悦康药业集团股份有限公司关于控股股 东部分股份被冻结的公告》（公告编号：2025-020）。 二、本次控股股东持有公司股份被解除冻结的情况 近日，公司控股股东京悦永顺收到北京市第二中级人民法院执行裁定书 （（2025）京 02 执恢 18 号），并转达公司。京悦永顺所持公司股份因司法拍卖的 26,500,000 股公司股份已完成过户登记。具体详见公司同日在上海证券交易所网 站（www.sse.com.cn）及指定媒体披露的《关于公司控股股东所持部分股份被 ...

Core Viewpoint - The stock price of Yuekang Pharmaceutical has experienced significant volatility, dropping over 20% after a major shareholder's shares were auctioned, followed by a rapid increase of 72.68% within three weeks due to market speculation and subsequent auctions [2][3] Financial Performance - In Q1 2025, Yuekang Pharmaceutical reported a 40.35% year-on-year decline in revenue, continuing a trend of decreasing profits with a net profit drop of 33% in 2024 [3][5] - The company's revenue for the full year 2024 was 37.81 billion yuan, down 9.90% from the previous year, with core product revenues from cardiovascular and anti-infection categories declining by 20.73% and 22.67% respectively [6] - The company has faced three consecutive years of declining performance, with a 44.78% drop in net profit in 2024 [6] Product Dependency and Market Challenges - The core product, Ginkgo biloba extract injection, previously contributed over 70% of the company's revenue but has faced pricing pressures leading to a 20.73% revenue decline [4][9] - The company opted out of hospital procurement markets to avoid further price drops, resulting in a significant reduction in sales volume [4][9] Debt and Legal Issues - The major shareholder is embroiled in legal disputes, which have led to the auction of 26.5 million shares, reflecting deeper financial troubles within the company [7][8] - As of the end of 2024, the company had 6 billion yuan in cash but also 6.9 billion yuan in interest-bearing debt, indicating a precarious financial position [6][9] Strategic Transition and R&D Challenges - Since its IPO in 2020, the company has been attempting to shift towards innovative drug development, increasing R&D investment from 2.94% in 2019 to 11.16% in 2024 [9][10] - However, several R&D projects have faced delays and cancellations, highlighting challenges in transitioning from traditional to innovative business models [10]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

一、函告主要内容： 1、药品名称：YKYY029 注射液 2、IND 编号：176571 证券代码：688658 证券简称：悦康药业 公告编号：2025-033 悦康药业集团股份有限公司 关于自愿披露子公司 YKYY029 注射液 获得 FDA 临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 悦康药业集团股份有限公司（以下简称"公司"）子公司北京悦康科创医 药科技股份有限公司（以下简称"悦康科创"）于近日获得美国食品药品监督 管理局（以下简称"FDA"）关于同意 YKYY029 注射液用于治疗高血压进行 临床试验的函告（Study May Proceed Letter，IND 编号：176571）。现将相关情 况公告如下： 3、申请适应症：高血压 有全球独占权益。 该产品近日也已获得国家药品监督管理局（以下简称"NMPA"）核准签 发的关于 YKYY029 注射液用于治疗高血压的《药物临床试验批准通知书》 （通知书编号：2025LP01808），具体内容详见《悦康药业集团股份有限公司 关于自愿披露子公司 ...